EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Micromem Technologies Inc. - Exhibit 99.1 - Filed by newsfilecorp.com

 

 

 

 

Condensed Consolidated Financial Statements of

MICROMEM TECHNOLOGIES INC.

For the three and nine months ended July 31, 2017 and 2016

(Expressed in United States Dollars)

 

1


MICROMEM TECHNOLOGIES INC.

Condensed Consolidated Interim Financial Statements
For the nine months ended July 31, 2017

(Expressed in United States Dollars)

Notice of No Auditors Review of Interim Financial Statements

In accordance with National Instrument 51-102 released by the Canadian Securities Administrators, the Company discloses that its auditors have not reviewed the unaudited financial statements for the nine months ended July 31, 2017 which have been prepared by and are the responsibility of the Company’s management.

2


MICROMEM TECHNOLOGIES INC.
CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(Expressed in United States dollars)

    July 31,     October 31,  
    2017     2016  
Assets            
Current assets:            
       Cash $  32,473   $  288,128  
       Deposits and other receivables (Note 5)   57,896     33,327  
    90,369     321,455  
             
Property and equipment, net   10,769     10,988  
Patents, net (Note 7)   414,525     403,600  
  $  515,663   $  736,043  
             
Liabilities and Shareholders' Equity            
Current liabilities:            
       Accounts payable and accrued liabilities $  1,094,339   $  917,179  
       Bridge loans (Note 9)   4,739,516     3,637,008  
       Derivative liability (note 9)   39,388     83,998  
  $  5,873,243   $  4,638,185  
Shareholders' Equity            
       Share capital: (Note 8)            
                Authorized: 
                        2,000,000 special preference shares, redeemable, voting 
                        Unlimited common shares without par value 
                Issued and outstanding: 
                        207,791,983 common shares (2016: 204,388,569) (Note 8)
$  76,665,196   $  75,855,139  
       Subscription received   -     -  
       Equity component of bridge loans (note 9)   23,075     23,075  
       Contributed surplus   27,360,676     26,918,470  
       Deficit   (109,406,527 )   (106,698,826 )
    (5,357,580 )   (3,902,142 )
             
  $  515,663   $  736,043  

"Joseph Fuda" (Signed)  
Joseph Fuda, Director  
   
"David Sharpless" (Signed)  
David Sharpless, Director  

See accompanying notes.

3


MICROMEM TECHNOLOGIES INC.
CONDENSED STATEMENTS OF CONSOLIDATED LOSS AND COMPREHENSIVE LOSS
(Expressed in United States dollars)

For the three and nine months ended July 31, 2017 and 2016 (Unaudited).

    Three months Ended July 31     Nine months Ended July 31  
    2017     2016     2017     2016  
                         
 Costs and expenses :                        
 Administration (Note 11) $  91,624   $  145,532   $  238,195   $  308,763  
 Professional, other fees and salaries (Note 11)   323,746     417,870     1,226,921     1,359,079  
 Stock based compensation (Note 8)   -     -     442,206     (85,500 )
 Development costs, net (Note 6)   49,156     3,778,776     270,013     3,782,194  
 Travel and entertainment   28,533     64,437     92,649     144,512  
 Amortization of property and equipment   921     1,327     3,045     3,952  
 Amortization of patents   33,555     -     94,620     -  
 Foreign exchange (gain) loss   17,406     (21,821 )   114,415     (33,403 )
 Loss from operations   544,941     4,386,121     2,482,064     5,479,597  
                         
 Other income and expenses                        
 Interest expense   173,553     167,349     488,667     377,832  
 Accretion expense (Note 9)   166,958     56,963     464,717     115,629  
 (Gain) loss on revaluation of derivative liability (Note 9)   (485,171 )   -     (727,747 )   -  
                         
Net income (loss) before income taxes   (400,281 )   (4,610,433 )   (2,707,701 )   (5,973,058 )
                         
 Income taxes (Note 10)   -     -     -     -  
                         
 Net income (loss) and comprehensive loss $  (400,281 ) $  (4,610,433 ) $  (2,707,701 ) $  (5,973,058 )
                         
Income (loss) per share - basic and diluted (Note 8) $  (0.00 ) $  (0.02 ) $  (0.01 ) $  (0.03 )
                         
Weighted average number of shares (Note 8)   206,057,820     200,629,426     205,115,725     198,017,961  

See accompanying notes.

4


MICROMEM TECHNOLOGIES INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Expressed in United States dollars)

For the three and nine months ended July 31, 2017 and 2016 (Unaudited).

    Three Months Ended July 31     Nine Months Ended July 31  
    2017     2016     2017     2016  
Cash flows from operating activities:                        
     Net income (loss) $  (400,281 ) $  (4,610,433 ) $  (2,707,701 ) $  (5,973,058 )
     Adjustments to reconcile loss for the period to
     net cash used in operating activities:
               
           Amortization of patents intangible assets   33,555     -     94,620     -  
           Amortization of property and equipment   921     1,327     3,045     3,952  
           Development costs   49,156     3,974,939     270,013     3,974,939  
           Accretion expense   166,958     56,963     464,717     115,629  
           Stock based compensation   -     -     442,206     (85,500 )
           (Gain) loss on revaluation of derivatives   (485,171 )   -     (727,747 )   -  
           Increase (decrease) in deposits and other receivables   (12,857 )   (145,905 )   (24,569 )   (204,157 )
           (Decrease) increase in accounts payable and
           accrued liabilities
  220,888     (195,663 )   141,480     97,057  
Net cash used in operating activities   (426,831 )   (918,772 )   (2,043,936 )   (2,071,138 )
                         
Cash flows from investing activities:                        
       Purchase of property and equipment   -     -     (3,807 )   -  
       Patents   (37,902 )   (26,118 )   (105,544 )   (167,570 )
       Deferred development costs   -     (197,120 )   -     (1,101,177 )
       Recovery of deferred development costs   -     -     -     443,901  
Net cash used in investing activities   (37,902 )   (223,238 )   (109,351 )   (824,846 )
                         
Cash flows from financing activities:                        
     Issue of common shares   367,739     880,464     649,232     990,464  
     Bridge loans advances   83,500     239,082     1,076,482     1,598,514  
     Bridge loan repayments   (82,361 )   (66,887 )   (237,941 )   (129,987 )
     Bridge loans Interest accrued   173,553     144,882     488,667     354,241  
Bridge loan converted in common shares   (78,808 )   -     (78,808 )   -  
     Subscription received   -     -     -     -  
Net cash provided by financing activities   463,623     1,197,541     1,897,632     2,813,232  
                         
Increase (decrease) in cash   (1,110 )   55,531     (255,655 )   (82,752 )
                         
Cash, beginning of period   33,583     20,285     288,128     158,568  
                         
Cash, end of period $  32,473   $ 75,816   $  32,473   $ 75,816  
                         
Supplemental cash flow information:                        
     Interest paid (classified in operating activities)   82,361     66,887     237,941     129,987  
     Shares issued on settlement of accounts payable   -                    
     Shares issued on settlement of legal claim   -     -     -     -  
     Shares issued on conversion of bridge loan                        

See accompanying notes.

5


MICROMEM TECHNOLOGIES INC.
Condensed Consolidated Statements of Changes in Shareholders' Equity
(Expressed in United States dollars)

    Number of     Share      Subscription       Contributed     Equity component     Deficit     Total  
    Shares     capital      received     Surplus     of Bridge loan              
Balance as at November 1, 2015   197,176,368   $  74,083,975   $ -   $  27,213,204   $ -   $ (99,893,291 ) $  1,403,888  
                                           
Private placement of units for cash   366,668     110,000     -     -     -     -     110,000  
Options exercised   3,756,366     751,273     -     -     -     -     751,273  
Fair value of options exercised   -     443,252     -     (443,252 )   -     -     -  
Common shares issued against payable   1,517,143     295,312     -     -     -     -     295,312  
Common shares issued against settlement of debt   312,500     62,500     -     -     -     -     62,500  
Common shares issued for conversion of bridge loan   509,524     108,827     -     -     (1,827 )   -     107,000  
Equity component of bridge loans   -     -     -     -     173,420     -     173,420  
Expiration of bridge loan equity conversion option   -     -     -     148,518     (148,518 )   -     -  
Treasury shares to be cancelled   750,000     -     -     -     -     -     -  
Net loss and comprehensive loss   -     -     -     -     -     (6,805,535 )   (6,805,535 )
Balance at October 31, 2016   204,388,569     75,855,139     -     26,918,470     23,075     (106,698,826 )   (3,902,142 )
                                           
Private placement of units for cash   3,333,914     649,232     -     -     -     -     649,232  
Common shares issued against payable   307,643     60,108     -     -     -     -     60,108  
Stock based compensation   -     -     -     442,206     -     -     442,206  
Subscription received   -     -     -     -     -     -     -  
Common shares issued against compensation   132,381     21,909     -     -     -     -     21,909  
Bridge loan converted into common shares   379,476     78,808     -     -     -     -     78,808  
Treasury shares cancelled   (750,000 )   -     -     -     -     -     -  
Net loss and comprehensive loss   -     -     -     -     -     (2,707,701 )   (2,707,701 )
Balance at July 31, 2017   207,791,983     76,665,196     -     27,360,676     23,075     (109,406,527 )     (5,357,580 )

6



MICROMEM TECHNOLOGIES INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
 
TABLE OF CONTENTS
 

  1.

Reporting Entity and Nature of Business

     
  2.

Going Concern

     
  3.

Basis of Presentation

     
  4.

Continuity of Significant Accounting Policies and Reporting Procedures

     
  5.

Deposits and Other Receivables

     
  6.

Deferred Development Costs

     
  7.

Patents

     
  8.

Share Capital, Stock Options and Loss per Share

     
  9.

Bridge Loans

     
  10.

Income Taxes

     
  11.

Expenses

     
  12.

Management Compensation and Related Party Transactions

     
  13.

Commitments

     
  14.

Contingencies

     
  15.

Subsequent Events

7



MICROMEM TECHNOLOGIES INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2017 and 2016
 

1.

REPORTING ENTITY AND NATURE OF BUSINESS

     

Micromem Technologies Inc. (“Micromem”) is incorporated under the laws of the Province of Ontario, Canada. The principal business address of the Company is 121 Richmond Street West, Suite 304, Toronto, Ontario, Canada.

     

Micromem develops, based upon proprietary technology, customized magnetic sensor applications for companies (referred to as “development partners”) operating internationally in various industry segments.

     

These consolidated financial statements include the accounts of Micromem and its wholly- owned subsidiaries:

     
(i)

Micromem Applied Sensors Technology, Inc. (“MAST”) incorporated in November 2007 and domiciled in Delaware, United States. MAST has the primary responsibility for the exploitation of the Company’s technologies in conjunction with various strategic partners and customers. Micromem and MAST are referred to interchangeably throughout these financial statements as “the Company”.

     
(ii)

7070179 Canada Inc., incorporated in October 2008 under the Canada Business Corporations Act in Ontario, Canada. The Company has assigned to this entity its rights, title and interests in certain patents which it previously held, directly in exchange for common shares of this entity.

     
(iii)

Memtech International Inc., Bahamas; Memtech International (USA) Inc., Delaware, United States; Pageant Technologies (USA) Inc., United States; Pageant Technologies Inc., Barbados; and Micromem Holdings (Barbados) Inc., Barbados. All of these entities are inactive.


These consolidated financial statements were authorized for issuance and release by the Company’s Board of Directors on September 29, 2017.

   
2.

GOING CONCERN

   

These consolidated financial statements have been prepared on the “going concern” basis in accordance with International Financial Reporting Standards (“IFRS”), which presumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future.

   

There are material uncertainties related to conditions and events that cast significant doubt about the Company’s ability to continue as a going concern for a reasonable period of time in future. During the nine months ended July 31, 2017, the Company reported a net loss and comprehensive loss of $2,707,701 (2016 - $5,973,058) and negative cash flow from operations of $2,043,936 (2016 - $2,071,138) measured as net loss reported with non-cash expenses added back. The Company’s working capital deficiency as at July 31, 2017 is $5,743,486 excluding consideration of the non-cash derivative liability as reported (as at October 31, 2016: $4,232,732).

8



MICROMEM TECHNOLOGIES INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2017 and 2016
 

The Company’s success depends on the profitable commercialization of its proprietary magnetic sensor technology. There is no assurance that the Company will be successful in the profitable commercialization of its technology. Based upon its current operating and financial plans, management of the Company believes that it will have sufficient access to financial resources to fund the Company’s planned operations in future; however, the ability of the Company to continue as a going concern is dependent upon its ability to secure additional financing and/or profitably commercialize its technology. These consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.

   

If the “going concern” assumption were not appropriate for these consolidated financial statements then adjustments would be necessary to the carrying value of assets and liabilities, the reported expenses and the balance sheet classifications used; in such cases, these adjustments would be material.

   
3.

BASIS OF PRESENTATION


  a)

Statement of Compliance with International Financial Reporting Standards:

     
 

These condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standards 34, Interim Financial Reporting (“IAS 34”) using accounting policies consistent with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and interpretations of the International Financial Reporting Interpretations Committee (“IFRIC”). Accordingly, they do not include all of the information required for annual financial statements and should be read in conjunction with the audited annual financial statement for the year ended October 31, 2016. The accounting policies adopted are consistent with those of the previous financial year and the corresponding interim reporting period.

     
  b)

Basis of measurement:

     
 

The Company’s condensed consolidated interim financial statements have been prepared on the historical cost basis except for certain non-current assets and financial statements, which are measured at fair value, as explained in Note 4, Continuity of Significant Accounting Policies.

9



MICROMEM TECHNOLOGIES INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2017 and 2016
 

  c)

Functional and presentation currency:

     
 

These consolidated financial statements are presented in United States dollars (“U.S. dollars”), which is also the Company’s and wholly-owned subsidiaries functional currency.

     
  d)

Critical accounting Judgements, Estimates and Assumptions:

     
 

The preparation of the consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

     
 

Information about judgments, assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment are as reported in the audited consolidated financial statements for the year ended October 31, 2016 and continue at July 31, 2017. These include estimates and assumptions utilized in determining fair values as required under IFRS, estimates related to the recovery of deferred development costs, capitalization criteria for patents, impairment of long-lived assets, deferred income taxes, functional currency and the assessment of material uncertainties.


4.

CONTINUITY OF SIGNIFICANT ACCOUNTING POLICIES AND REPORTING PROCEDURES


  a)

Accounting Policies:

     
 

These unaudited interim condensed consolidated financial statements follow the same accounting policies and methods of application as set in the audited consolidated financial statements for the year ended October 31, 2016 and should be read in conjunction with the audited consolidated financial statements. There have been no changes in accounting policies or methods of application of accounting policies in the nine month period ending July 31, 2017.

     
  b)

Fair Values:

     
 

There were no changes in the methods and assumptions used in estimating the fair value of the Company’s financial instruments and no changes to the classification of financial instruments in terms of the levels of financial hierarchy during the nine month period ending July 31, 2017 from those disclosed at October 31, 2016.

10



MICROMEM TECHNOLOGIES INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2017 and 2016
 

  c)

Capital Management:

     
 

There have been no changes to the objectives, policies and procedures that the Company has adopted and implemented with respect to capital management during the nine month period ending July 31, 2017 from those disclosed at October 31, 2016. The Company continues to closely monitor its accounts payable and debt service requirements. At July 31, 2017, it has implemented several go-forward cost reduction measures to reduce its monthly cash flow requirements.

     
  d)

Financial Risks:

     
 

The Company is exposed to and evaluates a variety of financial risks relative to its activities: market risk (including foreign exchange risk and interest rate risk), liquidity risk and credit risk. The overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects financial performance. Risk management is carried out under policies approved by the Board of Directors. Management is charged with the responsibility of establishing controls and procedures to ensure that financial risks are mitigated in accordance with the approved policies. The Company continues to closely monitor its working capital position as its primary liquidity risk.

     
  e)

New standards and interpretations issued but not yet adopted: The disclosures reported at October 31, 2016 relating to IFRS 15, IFRS 9, IAS7 and IFRS 16 remain valid at July 31, 2017. The Company is currently assessing the impact of these standards which are effective for future reporting periods.


5.

DEPOSITS AND OTHER RECEIVABLES

   

The balance reported as Deposits and other receivables consists of:


    July 31,     October 31,  
    2017     2016  
             
Advances to employee   5,065     7,586  
Prepaid insurance and other   52,831     25,741  
$ 57,896   $  33,327  

As at July 31, 2017, advances to employee consisted of a net advance of $5,065 (October 31, 2016: $7,586). This advance is non-interest-bearing, unsecured and due on demand. It is being repaid against wages earned by this employee.

11



MICROMEM TECHNOLOGIES INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2017 and 2016
 

6.

DEFERRED DEVELOPMENT COSTS

   

The breakdown of development costs that have been capitalized is as follows:


    July 31,     October 31,  
    2017     2016  
             
Opening balance $  -   $  3,070,299  
Additional project costs incurred   -     1,186,720  
Recovery of development costs   -     (643,901 )
Writedown of project costs   -     (3,613,118 )
Closing balance $  -   $  -  

To date, the Company has recovered from its development partners a portion of the costs it has incurred as development costs coincident with meeting milestones as stipulated in development contracts.

The Company wrote-off the capitalized cost of $3,613,118 in the third quarter of the year ended October 31, 2016 to reduce the carrying value of those projects to a value of nil given the uncertainty of realization of these costs. The Company anticipates that it may realize commercial economic benefits from the exploitation of these development projects in the future. Development costs incurred since August 1, 2016 are charged to expense in the period incurred. In the nine months ended July 31, 2017 the Company incurred $566,013 of development costs and recovered $296,000 from its development partners, to report net development expenses of $270,013 in the statement of consolidated loss.

12



MICROMEM TECHNOLOGIES INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2017 and 2016
 

7.

PATENTS


Cost      
       
At November 1, 2015 $  428,308  
Additions   192,873  
Year ended October 31, 2016 $  621,181  
       
At November 1, 2016 $  621,181  
Additions   105,544  
Nine months ended July 31, 2017 $  726,725  
       
Amortization      
       
At November 1, 2015 $  119,066  
Amortization for the year   98,515  
Year ended October 31, 2016 $  217,581  
       
At November 1, 2016 $  217,581  
Amortization for the period   94,620  
Nine months ended July 31, 2017 $  312,200  
       
Net book value at October 31, 2016 $  403,600  
Net book value at July 31,2017 $  414,525  

13



MICROMEM TECHNOLOGIES INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2017 and 2016
 

8.

SHARE CAPITAL, STOCK OPTIONS AND LOSS PER SHARE

     
a)

Share Capital

     

Authorized and outstanding:

     

The Company has two classes of shares as follows:


  i)

Special redeemable voting preference shares, 2,000,000 authorized, none are issued and outstanding.

     
  ii)

Common shares without par value – an unlimited number authorized.


      Number of     Amount  
      Shares     $   
               
  Balance at November 1, 2015   197,176,368   $  74,083,975  
               
  Private placement of shares for cash   366,668     110,000  
  Options exercised   3,756,366     751,273  
  Fair value of options exercised   -     443,252  
  Shares issued on settlement of accounts payable   1,517,143     295,312  
  Shares issued on settlement of legal claim   312,500     62,500  
  Shares issued on settlement of bridge loan   509,524     107,000  
  Equity component of bridge loan         1,827  
  Treasury shares to be cancelled   750,000     -  
  Balance at October 31, 2016   204,388,569   $  75,855,139  
               
  Private placement of common shares for cash   3,333,914     649,232  
  Shares issued on settlement of accounts payable   147,643     28,585  
  Shares issued on settlement of wages   292,381     53,432  
  Treasury shares cancelled   (750,000 )   -  
  Bridge loan converted   379,476     78,808  
               
  Balance at July 31, 2017   207,791,983   $  76,665,196  

  b)

Stock Options

     
 

Stock option plan:

     
 

The Company has a fixed stock option plan. Under the Company’s stock option plan (the “Plan”), the Company may grant options for up to 18,840,000 shares of common stock to directors, officers, employees or consultants of the Company and its subsidiaries. The exercise price of each option is equal to or greater than the market price of the Company’s shares on the date of grant unless otherwise permitted by applicable securities regulations. An option’s maximum term under the Plan is 10 years. Stock options are fully vested upon issuance by the Company unless the Board of Directors stipulates otherwise by Directors’ resolution.

14



MICROMEM TECHNOLOGIES INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2017 and 2016
 

A summary of the status of the Company’s fixed stock option plan through July 31, 2017 and changes during the periods is as follows:

            Weighted        
            average        
            exercise     Proceeds  
      Options     price     realized  
      (000 )   $        
  Outstanding, November 01, 2015   9,817     0.31        
  Granted   -     -        
  Exercised   (3,756 )   (0.20 )   751,273  
  Expired   (1,666 )   (0.21 )      
  Outstanding, October 31, 2016   4,395     0.45        
  Granted   2,890     0.22        
  Expired   (690 )   (0.35 )      
  Outstanding, July 31, 2017   6,595     0.36        

The weighted average share price on the dates of exercise was $0.36.

During the year ended October 31, 2016 the Company issued a total of nil stock options. On November 7, 2016, the Company issued a total of 2,890,000 stock options. All options vest immediately upon issuance.

15



MICROMEM TECHNOLOGIES INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2017 and 2016
 

8.

SHARE CAPITAL, STOCK OPTIONS AND LOSS PER SHARE (Cont’d)

   

The Company has the following stock options outstanding at July 31 2017:


        Weighted  
        average  
        remaining  
        life (in  
  Date of Issue #Issued Strike Price $ years) Expiry Date
           
  January 22, 2013 440,000 0.30 CDN 0.80 January 22, 2018
  September 16, 2013 520,000 0.27 CDN 1.30 September 16, 2018
  February 10, 2014 350,000 0.85 1.70 February 10, 2019
  April 25, 2014 230,000 0.64 1.90 April 25, 2019
  June 4, 2015 975,000 0.49 3.00 June 4, 2020
  August 20, 2015 940,000 0.46 3.30 August 20, 2020
  September 30, 2015 250,000 0.40 3.40 September 30, 2020
  November 7, 2016 2,890,000 0.22 4.60 November 7, 2021
    6,595,000      

All outstanding options at July 31, 2017 are exercisable. In the quarter ended January 31, 2017, the Company recorded a total expense of $442,206 (2016 - $nil) with respect to the issuance of options issued during the three months then ended, calculated in accordance with the Black Scholes option-pricing model.

The underlying assumptions in the Black Scholes option-pricing model were as follows:

    2017  
Share price $  0.22  
Volatility factor (based on historical v   102%  
Risk free interest rate   0.72%  
Expected life   5 years  
Dividend yield   0%  
Forfeiture rate   0%  

16



MICROMEM TECHNOLOGIES INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2017 and 2016
 

c)        Loss Per Share

The calculation of basic and diluted loss per share for the quarter ended July 31, 2017 was based on the loss attributable to common shareholders of $400,281 (2016 - $4,610,433) divided by the weighted average number of common shares outstanding of 206,057,820 (2016 – 200,629,426).

Diluted loss per share does not include the effect of 6,595,000 stock options outstanding as they are anti-dilutive.

9. BRIDGE LOANS
   
  2016 Bridge Loans:

  (1)

The bridge loans outstanding at October 31, 2016 and for the year then ended are summarized as below.


    October 31,2016
    $USD $CDN Total
     denominated loans denominated loans  
    ($US) ($US)  
         
  Debt obligations                        853,496 2,783,512 3,637,008
  Equity portion of bridge loans 23,075 - 23,075
  Derivative Liability - 83,998 83,998

    Year ended October 31, 2016
    $USD $CDN Total
    denominated loans denominated loans  
    ($US) ($US)  
         
  Accretion expense 87,184 427,37 7 514,561  
  Interest expense 193,254 368,354   561,608  
  (Gain)/loss on extinguishment of debt - 8,223   8,223  
  Gain/(loss) on revaluation of derivatives - (295,616) (295,616)

17



MICROMEM TECHNOLOGIES INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2017 and 2016
 

  (2)

The Company completed the following bridge loan transactions in the 2016 fiscal year:

       
  (a)

It secured an additional 7 bridge loans denominated in $USD. These loans were of a short term nature and were extended on several occasions during 2016; these loans have now been extended to June-November 2017.

       
  (b)

It secured an additional 6 bridge loans denominated in $CDN. These loans were of a short term nature and were extended on several occasions during 2016; these loans have now been extended to June-November 2017.

2017 Bridge Loans:

  (1)

The bridge loans outstanding at April 30, 2017 and for the 6 months then ended are summarized as below:


    Nine months ended July 31,2017
    $USD $CDN Total
    denominated loans denominated loans  
    ($US) ($US)  
         
         
  Debt obligations                              949,227 3,790,289 4,739,516
  Equity portion of bridge loans 23,075 - 23,075
  Derivative Liability - 39,388 39,388

    Nine months ended July 31, 2017
    $USD $CDN Total
    denominated loans  denominated loans   
    ($US) ($US)  
         
  Accretion expense 11,355 453,362    464,717
  Interest expense                                116,824 371,843    488,667
  Gain (loss) on revaluation of derivatives - 727,747    727,747

In the quarter ending January 31, 2017, the Company secured an additional 10 bridge loans denominated in $CDN totaling $868,000 CDN ($651,685 USD). The interest rate on 9 of these loans is 1% per month in each case and the conversion price to common shares is stipulated as $0.30 CDN. The 10th bridge loan bears interest at 2% per month and is not convertible.

18



MICROMEM TECHNOLOGIES INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2017 and 2016
 

In the quarter ended April 30, 2017, the Company secured an additional 4 bridge loans denominated in $CDN totaling $444,000 CDN ($325,905 USD). The interest rate on these loans is 1% per month in each case and the conversion price is stipulated as $0.23 CDN.

   

In the quarter ended July 31, 2017, the Company secured an additional bridge loan in the amount of $83,500. The interest rate on this loan was 1% per month; the loan is non-convertible. The two convertible $USD loans that matured in June 2017 were extended through October 2017.

   
10.

INCOME TAXES


  (a)

The Company has non-capital losses of approximately $23.9 million available to reduce future taxable income, the benefit of which has not been recognized in these consolidated financial statements. As of July 31, 2017 the tax losses expire as follows:


          Other        
    Canada     foreign     Total  
2022   -     7,301     7,301  
2023   -     9,667     9,667  
2025   -     14,471     14,471  
2026   1,791,571     5,254     1,796,825  
2027   1,506,571     3,459     1,510,030  
2028   7,812     55,519     63,331  
2029   1,544,035     463,610     2,007,645  
2030   2,083,306     1,886,778     3,970,084  
2031   1,255,127     48,808     1,303,935  
2032   1,391,007     333,962     1,724,969  
2033   1,686,037     160,550     1,846,587  
2034   2,439,124     682,878     3,122,002  
2035   2,827,284     573,235     3,400,519  
2036   2,574,031     580,898     3,154,929  
$ 19,105,905   $  4,826,390   $  23,932,295  

  (b)

In addition the Company has available capital loss carry forwards of approximately $1.2 million to reduce future taxable capital gains, the benefit of which has not been recognized in these consolidated financial statements. These losses carry forward indefinitely.

19



MICROMEM TECHNOLOGIES INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2017 and 2016
 

11.

EXPENSES

Administration

   

The components of general and administration expenses are as follows (9 months):


    2017     2016  
             
General and administrative $  67,836   $  148,787  
Rent and occupancy cost   53,493     55,007  
Insurance   54,023     47,401  
Telephone   9,951     8,946  
Investor relations, listing and filling fees   52,892     48,622  
  $  238,195   $  308,763  

Professional, Other Fees and Salaries

The components of professional, other fees and salaries expenses are as follows (9 months):

    2017     2016  
             
Professional fees $  236,596   $  263,486  
Consulting fees   656,899     813,708  
Salaries and benefits   333,426     281,885  
  $  1,226,921   $  1,359,079  

12.

MANAGEMENT COMPENSATION AND RELATED PARTY TRANSACTIONS

   

The Company reports the following related party transactions:


  (a)

Management and consulting fees:

     
 

Included in professional fees, other fees and salaries as reported are management fees and consulting fees paid or payable to individuals (or companies controlled by such individuals) who serve as officers, directors and employees of the Company. The total compensation paid to such parties is summarized as (9 months):

20



MICROMEM TECHNOLOGIES INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2017 and 2016
 

    2017     2016  
Cash compensation $  567,354   $  532,974  
Less portion capitalized            
to deferred development costs   -     (4,869 )
    567,354     528,105  
             
Stock based compensation   315,968     -  
             
  $  883,322   $  528,105  

 

In the quarter ended January 31, 2017, these parties were awarded a total of 2,065,000 options at an exercise price of $0.22 per share.

     
  (b)

Bridge Loan:

     
 

The CEO provided a bridge loan of $100,000 CDN on September 2, 2016. That loan was converted to common shares in July 2017.

     
  (c)

In the quarter ended July 31, 2017, the CEO and the CFO completed private placements to convert accrued fees payable to them at that date to common shares.

     
 

The President of MAST provided a $40,000 advance to the Company in August 2016. The Company reports a balance payable at July 31, 2017 to the President of MAST of $134,141, including this advance and accrued fees and expenses payable at that date.


13.

COMMITMENTS

   

The Company has extended its lease for premises through July 2022. The monthly lease payments are $4,005 CDN plus operating costs and taxes, for a total of $7,500 CDN per month.

   

The Company has certain outstanding commitments to third party subcontractors with respect to its ongoing product development initiatives. These commitments total $1,341,881 over the next one to three years. These commitments will become obligations of the Company as and when this work is commissioned to start by the Company, which will be initiated once the Company secures the requisite financing.

21



MICROMEM TECHNOLOGIES INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2017 and 2016
 

14.

CONTINGENCIES

     
(a)

The Company has agreed to indemnify its directors and officers and certain of its employees in accordance with the Company’s by-laws. The Company maintains insurance policies that may provide coverage against certain claims.

     
(b)

In addition to the above, the Company may be subject to litigation, claims and governmental and regulatory proceedings arising in the ordinary course of business. In such cases, the Company accrues a loss contingency for these matters when it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. At July 31, 2017, there are no known outstanding legal claims to which the Company is a party.


15.

SUBSEQUENT EVENTS

     

The Company reports the following events:

     
(a)

It secured a bridge loan of $155,000 at a rate of 5% per annum compounding monthly. The loan is non-convertible and has a term of 12 months. It can be prepaid at the Company’s option within the first six months of the term of the loan.

     
(b)

It completed two private placements and secured a total of $66,000 CDN ($51,968 USD) of financing.

     
(c)

It continues its negotiations with its major partners under its product development agreements.

     
(d)

It has effected certain cost containment and reduction measures to reduce its monthly cash requirements.

**********

22